Mori, Takehiko

写真a

Affiliation

School of Medicine, Department of Internal Medicine (Hematology) Division of Hematology, Department of Medicine Keio University School of Medicine (Shinanomachi)

Position

Associate Professor

E-mail Address

E-mail address

Related Websites

External Links

Profile 【 Display / hide

  • Major research interest focuses on the diagnosis, treatment, and management of complications of benign and malignant hematological disorders, improvement of the outcome of hematopoietic stem cell transplantation, and opportunistic infection.

Other Affiliation 【 Display / hide

  • School of Medicine, 感染制御センター, Vice Manager

Academic Background 【 Display / hide

  • 1993.03

    Keio University School of Medicine, School of Medicine

    University

Academic Degrees 【 Display / hide

  • 医学博士, Keio University, 1999.02

    マウスサイトメガロウイルス急性感染による骨髄造血前駆細胞のアポトーシスの誘導について

Licenses and Qualifications 【 Display / hide

  • Medical Lincense, 1993.05

  • Board Certified Hematologist

  • Board Certified Trainer of Japanese Society of Hematology

  • Board Certified Member of Japanese Society of Infectious Diseases

  • Fellow of Board Certified Trainer of Japanese Society of Infectious Diseases

display all >>

 

Research Areas 【 Display / hide

  • Hematology

  • Infectious disease medicine

Research Keywords 【 Display / hide

  • Nosocomial Infection

  • Hematology

  • Hematological Malignancy

  • Hematopoietic Stem Cell Transplantation

 

Books 【 Display / hide

  • チーム医療のための造血細胞移植ガイドブック

    MORI TAKEHIKO, 医薬ジャーナル社, 2018.04

    Scope: 造血細胞移植の合併症

  • 今日の治療指針 私はこう治療している 2018年

    MORI TAKEHIKO, 医学書院, 2018.04

    Scope: 造血幹細胞移植(適応と方法)

  • がん口腔支持療法

    MORI TAKEHIKO, 永末書店, 2017.04

    Scope: 造血幹細胞移植における口腔合併症

  • 今日の治療指針 私はこう治療している 2017年

    MORI TAKEHIKO, 医学書院, 2017.04

    Scope: 顆粒球減少症

  • 慢性骨髄性白血病(CML)の基礎と臨床

    MORI TAKEHIKO, 医薬ジャーナル社, 2017.01

    Scope: 同種造血幹細胞移植の位置づけ

display all >>

Papers 【 Display / hide

  • Factors affecting lower limb muscle strength and cardiopulmonary fitness after allogeneic hematopoietic stem cell transplantation

    Ishikawa A., Otaka Y., Kamisako M., Suzuki T., Miyata C., Tsuji T., Matsumoto H., Kato J., Mori T., Okamoto S., Liu M.

    Supportive Care in Cancer (Supportive Care in Cancer)  27 ( 5 ) 1793 - 1800 2019.05

    ISSN  09414355

     View Summary

    © 2018, The Author(s). Purpose: The aim of this study is to clarify the factors affecting physical function after allogeneic hematopoietic stem cell transplantation (HSCT). Methods: We retrospectively analyzed 88 patients (median age, 44.5 years) who received allogeneic HSCT. Leg extension torque and peak oxygen consumption (VO 2 ) were evaluated before and after HSCT. Patient factors (age, sex, underlying diseases, hemoglobin, serum albumin, and Karnofsky performance status score before transplant) and transplant factors (conditioning regimen, days to neutrophil engraftment, grades of acute graft-versus-host disease [GVHD], infections, and the interval between pre- and post-evaluation) were collected via chart review, and were used for correlational and comparison analyses in order to identify the variables associated with reduced post-HSCT leg extension torque and peak VO 2 . Stepwise multiple regression analyses for post-HSCT leg extension torque and post-HSCT peak VO 2 were performed using age, sex, and the related variables with a p value < 0.2 in the correlational and comparison analyses. Results: Leg extension torque and peak VO 2 were significantly reduced after HSCT (p < 0.001). Pre-HSCT leg extension torque, grades of acute GVHD, age, and the interval between pre- and post-evaluation were identified as significant factors associated with reduced post-HSCT leg extension torque. However, none of these factors were significantly associated with reduced post-HSCT peak VO 2 , and only its pre-transplant value was identified as a significant factor. Conclusions: These findings suggest that improvements in muscle strength and cardiopulmonary fitness before HSCT are crucial for maintaining post-treatment physical function, especially in elderly individuals with acute GVHD requiring a long-term stay in a protective environment.

  • Induction chemotherapy followed by allogeneic HCT versus upfront allogeneic HCT for advanced myelodysplastic syndrome: A propensity score matched analysis

    Konuma T., Shimomura Y., Ozawa Y., Ueda Y., Uchida N., Onizuka M., Akiyama M., Mori T., Nakamae H., Ohno Y., Shiratori S., Onishi Y., Kanda Y., Fukuda T., Atsuta Y., Ishiyama K.

    Hematological Oncology (Hematological Oncology)  37 ( 1 ) 85 - 95 2019.02

    ISSN  02780232

     View Summary

    © 2018 John Wiley & Sons, Ltd. To reduce post-transplant relapse, acute myeloid leukemia (AML) type remission induction chemotherapy has been attempted to reduce disease burden before allogeneic hematopoietic cell transplantation (HCT) in patients with advanced myelodysplastic syndrome (MDS). However, the efficacy of induction chemotherapy before HCT is unclear. We retrospectively analyzed the Japanese registration data of 605 adult patients, who had received allogeneic HCT for advanced MDS between 2001 and 2016, to compare the post-transplant relapse between patients who received induction chemotherapy followed by allogeneic HCT and those who received upfront HCT. Propensity score matching identified 230 patients from each cohort. There were no significant differences in overall survival and non-relapse mortality between the two groups. The cumulative incidence of relapse was significantly higher in patients who received induction chemotherapy than those who received upfront HCT. In the subgroup analyses, upfront HCT had a significantly reduced relapse incidence among patients with poor cytogenetics, those with higher international prognostic scoring system at diagnosis, and those who received reduced-intensity conditioning. Our results suggested that AML type remission induction chemotherapy before HCT did not improve post-transplant relapse and survival for adult patients with advanced MDS. Upfront HCT is preferable for patients with a poor karyotype.

  • Hematopoietic Cell Transplantation for Acute Panmyelosis with Myelofibrosis: A Retrospective Study in Japan

    Konuma T., Kondo T., Kawata T., Iwato K., Sato Y., Mori T., Ohashi K., Nakazawa H., Sugahara H., Ago H., Eto T., Imamura Y., Fukuda T., Kanda Y., Atsuta Y., Yano S.

    Biology of Blood and Marrow Transplantation (Biology of Blood and Marrow Transplantation)  25 ( 1 ) e23 - e27 2019.01

    ISSN  10838791

     View Summary

    © 2018 Acute panmyelosis with myelofibrosis (APMF) is a rare subtype of acute myeloid leukemia characterized by acute onset of cytopenias and bone marrow fibrosis in the absence of splenomegaly. Because the prognosis of APMF is extremely poor even after chemotherapy, hematopoietic cell transplantation (HCT) has been used to treat APMF. However, the outcome after HCT for APMF remains unclear. To evaluate the outcomes and prognostic factors after HCT as a therapeutic modality for APMF, we retrospectively analyzed the Japanese registration data of 40 APMF patients who received allogeneic and syngeneic HCT between 2005 and 2015. The median age at HCT was 53.5 years (range, 16 to 70). The disease status at HCT was first complete remission (CR1) in 13 patients (33%). The probability of overall survival and the cumulative incidence of relapse at 3 years were 24% and 59%, respectively. Univariate analysis identified that female sex and disease status CR1 at the time of HCT were significantly associated with higher overall survival. Although APMF patients have a poor long-term prognosis even after syngeneic and allogeneic HCT, these data suggested that allogeneic HCT offered a curative option for APMF.

  • A rare case of an acquired factor V inhibitor in a patient with myelodysplastic syndrome during azacitidine treatment.

    Fujita Y, Nakazato T, Ito C, Masuda K, Osada Y, Aisa Y, Mori T

    Ann Hematol 97 ( 10 ) 2009 - 2010 2018.10

    Research paper (scientific journal), Joint Work

  • The prognostic value of positron emission tomography/computed tomography in rheumatoid arthritis patients with methotrexate-associated lymphoproliferative disorders.

    Takanashi S, Nakazato T, Aisa Y, Ito C, Arakaki H, Osada Y, Hirano M, Mori T.

    Ann Hematol 97 ( 9 ) 1611 - 1618 2018.09

    Research paper (scientific journal), Joint Work

display all >>

Papers, etc., Registered in KOARA 【 Display / hide

Presentations 【 Display / hide

  • 同種造血幹細胞移植後の血清IgG2サブクラス濃度の検討。

    山崎理絵、森 毅彦。

    第65回日本臨床検査医学会学術集会 (東京) , 2018.11, Oral Presentation(general)

  • EBV移植後リンパ増殖症に対するテトラマー解析とウイルス特異的CTL療法の有用性。

    西尾 信博, 三輪田 俊介, 成田 幸太郎, 北澤 宏展, 片岡 伸介, 濱田 太立, 市川 大輔, 谷口 理恵子, 村上 典寛, 鈴木 喬悟, 川島 希, 西川 英里, 奥野 友介, 成田 敦, 村松 秀城, 鈴木 律朗, 森 毅彦, 川端 浩, 小島 勢二, 高橋 義行

    第80回日本血液学会総会 (大阪) , 2018.10, Oral Presentation(general)

  • 巨脾を有する患者における赤血球輸血とフェリチン値の関連性に関する検討

    住谷 智恵子, 森 毅彦, 菊池 拓, 加藤 淳, 清水 隆之, 岡本 真一郎。

    第80回日本血液学会総会 (大阪) , 2018.10, Poster (general)

  • 当院におけるベンダムスチン再投与の有効性・安全性の検討。

    松木 絵里, 外山 高朗, 村上 紘一, 住谷 智恵子, 山根 裕介, 甲田 祐也, 櫻井 政寿, 雁金 大樹, 戸澤 圭一, 橋田 里妙, 安部 涼平, 城下 郊平, 佐藤 雄紀, 菊池 拓, 加藤 淳, 清水 隆之, 森 毅彦, 岡本 真一郎。

    第80回日本血液学会総会 (大阪) , 2018.10, Oral Presentation(general)

  • 診断後1年の治療効果は2005年NIH診断基準による慢性GVHDにおける予後予測因子となりうる。

    大和田 千桂子, 堺田 惠美子, 五十嵐 愛子, 土岐 典子, 森 毅彦, 加藤 淳, 金森 平和, 田中 正嗣, 藤澤 信, 大草 恵理子, 豊崎 誠子, 青山 泰之, 神田 善伸, 仲宗根 秀樹, 萩原 真紀, 清水 啓明, 加藤 せい子, 渡部 玲子, 鐘野 勝洋, 酒井 リカ, 齋藤 健, 臼杵 憲祐, 中世古 知昭, 岡本 真一郎。

    第80回日本血液学会総会, 2018.10, Oral Presentation(general)

display all >>

 

Courses Taught 【 Display / hide

  • CASE STUDIES OF INTERNAL MEDICINE

    2019

  • CLINICAL CLERKSHIP IN HEMATOLOGY

    2019

  • INFECTIOUS DISEASES

    2019

  • LECTURE SERIES, INTERNAL MEDICINE

    2019

  • LECTURE SERIES, INTERNAL MEDICINE (HEMATOLOGY)

    2019

Courses Previously Taught 【 Display / hide

  • Internal Medicine (Hematology)

    Keio University, 2017, Spring Semester, Lecture, Within own faculty

  • Internal Medicine (Hematology)

    Keio University, 2016, Spring Semester, Lecture, Within own faculty